Pharsight

Qnasl patents expiration

QNASL's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5605674 TEVA BRANDED PHARM Medicinal aerosol formulations
Feb, 2014

(10 years ago)

US5683677 TEVA BRANDED PHARM Medicinal aerosol formulations
Nov, 2014

(9 years ago)

US5776432 TEVA BRANDED PHARM Beclomethasone solution aerosol formulations
Jul, 2015

(8 years ago)

US7780038 TEVA BRANDED PHARM Dispensing apparatus with dosage counter
Jan, 2027

(2 years from now)

US10188811 TEVA BRANDED PHARM Nasal spray device
Oct, 2031

(7 years from now)

Qnasl is owned by Teva Branded Pharm.

Qnasl contains Beclomethasone Dipropionate.

Qnasl has a total of 5 drug patents out of which 3 drug patents have expired.

Expired drug patents of Qnasl are:

  • US5605674
  • US5683677
  • US5776432

Qnasl was authorised for market use on 17 December, 2014.

Qnasl is available in aerosol, metered;nasal dosage forms.

The generics of Qnasl are possible to be released after 21 October, 2031.

Drug Exclusivity Drug Exclusivity Expiration
New Strength(NS) Dec 17, 2017
New Product(NP) Mar 23, 2015

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Market Authorisation Date: 17 December, 2014

Treatment: NA

Dosage: AEROSOL, METERED;NASAL

More Information on Dosage

QNASL family patents

Family Patents